Managing drug-resistant epilepsy: challenges and solutions

Linda Dalic,1 Mark J Cook2,3 1Department of Neurology, Austin Health, 2St Vincent’s Hospital, Centre for Clinical Neurosciences and Neurological Research, 3Department of Medicine, The University of Melbourne, Melbourne, Australia Abstract: Despite the development of new antiepileptic...

Full description

Saved in:
Bibliographic Details
Main Authors: Dalic L, Cook MJ
Format: Article
Language:English
Published: Dove Medical Press 2016-10-01
Series:Neuropsychiatric Disease and Treatment
Subjects:
Online Access:https://www.dovepress.com/managing-drug-resistant-epilepsy-challenges-and-solutions-peer-reviewed-fulltext-article-NDT
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1839651654851362816
author Dalic L
Cook MJ
author_facet Dalic L
Cook MJ
author_sort Dalic L
collection DOAJ
description Linda Dalic,1 Mark J Cook2,3 1Department of Neurology, Austin Health, 2St Vincent’s Hospital, Centre for Clinical Neurosciences and Neurological Research, 3Department of Medicine, The University of Melbourne, Melbourne, Australia Abstract: Despite the development of new antiepileptic drugs (AEDs), ~20%–30% of people with epilepsy remain refractory to treatment and are said to have drug-resistant epilepsy (DRE). This multifaceted condition comprises intractable seizures, neurobiochemical changes, cognitive decline, and psychosocial dysfunction. An ongoing challenge to both researchers and clinicians alike, DRE management is complicated by the heterogeneity among this patient group. The underlying mechanism of DRE is not completely understood. Many hypotheses exist, and relate to both the intrinsic characteristics of the particular epilepsy (associated syndrome/lesion, initial response to AED, and the number and type of seizures prior to diagnosis) and other pharmacological mechanisms of resistance. The four current hypotheses behind pharmacological resistance are the “transporter”, “target”, “network”, and “intrinsic severity” hypotheses, and these are reviewed in this paper. Of equal challenge is managing patients with DRE, and this requires a multidisciplinary approach, involving physicians, surgeons, psychiatrists, neuropsychologists, pharmacists, dietitians, and specialist nurses. Attention to comorbid psychiatric and other diseases is paramount, given the higher prevalence in this cohort and associated poorer health outcomes. Treatment options need to consider the economic burden to the patient and the likelihood of AED compliance and tolerability. Most importantly, higher mortality rates, due to comorbidities, suicide, and sudden death, emphasize the importance of seizure control in reducing this risk. Overall, resective surgery offers the best rates of seizure control. It is not an option for all patients, and there is often a significant delay in referring to epilepsy surgery centers. Optimization of AEDs, identification and treatment of comorbidities, patient education to promote adherence to treatment, and avoidance of triggers should be periodically performed until further insights regarding causative pathology can guide better therapies. Keywords: drug-resistant epilepsy, pharmacoresistant, management, review 
format Article
id doaj-art-ab8fe8bfbb2d477ea9cc4f578cdcf3a9
institution Matheson Library
issn 1178-2021
language English
publishDate 2016-10-01
publisher Dove Medical Press
record_format Article
series Neuropsychiatric Disease and Treatment
spelling doaj-art-ab8fe8bfbb2d477ea9cc4f578cdcf3a92025-06-26T01:58:37ZengDove Medical PressNeuropsychiatric Disease and Treatment1178-20212016-10-01Volume 12Issue 12605261629385Managing drug-resistant epilepsy: challenges and solutionsDalic L0Cook MJ1Centre for Clinical Neurosciences and Neurological ResearchCentre for Clinical Neurosciences and Neurological ResearchLinda Dalic,1 Mark J Cook2,3 1Department of Neurology, Austin Health, 2St Vincent’s Hospital, Centre for Clinical Neurosciences and Neurological Research, 3Department of Medicine, The University of Melbourne, Melbourne, Australia Abstract: Despite the development of new antiepileptic drugs (AEDs), ~20%–30% of people with epilepsy remain refractory to treatment and are said to have drug-resistant epilepsy (DRE). This multifaceted condition comprises intractable seizures, neurobiochemical changes, cognitive decline, and psychosocial dysfunction. An ongoing challenge to both researchers and clinicians alike, DRE management is complicated by the heterogeneity among this patient group. The underlying mechanism of DRE is not completely understood. Many hypotheses exist, and relate to both the intrinsic characteristics of the particular epilepsy (associated syndrome/lesion, initial response to AED, and the number and type of seizures prior to diagnosis) and other pharmacological mechanisms of resistance. The four current hypotheses behind pharmacological resistance are the “transporter”, “target”, “network”, and “intrinsic severity” hypotheses, and these are reviewed in this paper. Of equal challenge is managing patients with DRE, and this requires a multidisciplinary approach, involving physicians, surgeons, psychiatrists, neuropsychologists, pharmacists, dietitians, and specialist nurses. Attention to comorbid psychiatric and other diseases is paramount, given the higher prevalence in this cohort and associated poorer health outcomes. Treatment options need to consider the economic burden to the patient and the likelihood of AED compliance and tolerability. Most importantly, higher mortality rates, due to comorbidities, suicide, and sudden death, emphasize the importance of seizure control in reducing this risk. Overall, resective surgery offers the best rates of seizure control. It is not an option for all patients, and there is often a significant delay in referring to epilepsy surgery centers. Optimization of AEDs, identification and treatment of comorbidities, patient education to promote adherence to treatment, and avoidance of triggers should be periodically performed until further insights regarding causative pathology can guide better therapies. Keywords: drug-resistant epilepsy, pharmacoresistant, management, review https://www.dovepress.com/managing-drug-resistant-epilepsy-challenges-and-solutions-peer-reviewed-fulltext-article-NDTDrug-resistant epilepsypharmacoresistantmanagementreview.
spellingShingle Dalic L
Cook MJ
Managing drug-resistant epilepsy: challenges and solutions
Neuropsychiatric Disease and Treatment
Drug-resistant epilepsy
pharmacoresistant
management
review.
title Managing drug-resistant epilepsy: challenges and solutions
title_full Managing drug-resistant epilepsy: challenges and solutions
title_fullStr Managing drug-resistant epilepsy: challenges and solutions
title_full_unstemmed Managing drug-resistant epilepsy: challenges and solutions
title_short Managing drug-resistant epilepsy: challenges and solutions
title_sort managing drug resistant epilepsy challenges and solutions
topic Drug-resistant epilepsy
pharmacoresistant
management
review.
url https://www.dovepress.com/managing-drug-resistant-epilepsy-challenges-and-solutions-peer-reviewed-fulltext-article-NDT
work_keys_str_mv AT dalicl managingdrugresistantepilepsychallengesandsolutions
AT cookmj managingdrugresistantepilepsychallengesandsolutions